{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-164004","form_type":"8-K","ticker":"RPRX","cik":"0001802768","company_name":"Royalty Pharma plc","filed_at":"2024-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.198951+00:00","generated_at":"2026-06-01T03:37:57.269191+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Royalty Pharma increases Evrysdi royalty stake to 90.5% for $242M from PTC option exercise","bullets":["PTC exercised option to sell half its retained Evrysdi royalty to Royalty Pharma for ~$242M upfront.","Royalty Pharma's Evrysdi royalty ownership increases from 81% to 90.5% (before cap).","Evrysdi (SMA drug) generated 2023 sales of ~CHF 1.4B ($1.6B), up 39% YoY at CER.","Total upfront investment in Evrysdi royalties now $1.9B; effective royalty rate 7.2%-14.5%.","PTC retains option to sell remaining 9.5% royalty for $250M less royalties received until Dec 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-164004","json":"https://secwatch.observer/filing/0001193125-24-164004.json","markdown":"https://secwatch.observer/filing/0001193125-24-164004.md","text":"https://secwatch.observer/filing/0001193125-24-164004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802768/000119312524164004/0001193125-24-164004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802768/000119312524164004/d724682d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T03:37:57.269191+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}